Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HIMS

Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem

Hims Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this time is not another flashy partnership — it's a rally built from within.

How To Buy HIMS For A 24% Discount, Or Achieve an 82% Annual Return

How To Buy HIMS For A 24% Discount, Or Achieve an 82% Annual Return

Yesterday, with Hims & Hers Health (HIMS) trading at $62.76, the November 7 put option with a strike price of $50 was trading around $2.45. Traders selling this put would receive $245 in option premium.

Investors Are Buying Hims & Hers Health Stock Following Wednesday's Platform Expansion Announcement

Investors Are Buying Hims & Hers Health Stock Following Wednesday's Platform Expansion Announcement

Hims Hers Health Inc (NYSE:HIMS) shares are trading higher Wednesday following the company’s launch of a new menopause and perimenopause care specialty on its Hers platform.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Healthcare Stocks Using AI to Drive Growth

AI is reshaping healthcare by improving outcomes and easing burnout. See how three companies are leading this transformation

Hims & Hers Powers YieldMax's Latest Options-Based Income ETF

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).

HIMS Stock Just Got Rocked (Again) By the FDA. This Analyst Still Thinks Hims & Hers Can Surge 50%.

Despite a sharp selloff after the latest FDA warning, Hims & Hers continues to post triple-digit annual gains and strong revenue growth, with at least one analyst projecting a 50% upside.

3 Big Short Interest Names With Bullish Setups

HIMS, DLO, and TEM combine high short interest with bullish chart setups, creating strong breakout potential as market momentum stays hot.

inkl

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy

Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy

Hims & Hers Health posted 73% revenue growth and 31% more subscribers in Q2. With analyst targets hitting $68, is now the time to buy HIMS?

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds

Oscar Health Inc (NYSE:OSCR) just became one of Wall Street's buzziest policy trades. With ACA (Affordable Care Act) subsidy chatter swirling ahead of a possible government shutdown, the tech-driven insurer is drawing Hims Hers Health Inc (NYSE:HIMS) style moonshot comparisons — and short sellers may be sitting on a powder…

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum.

FDA takes aim at Hims and other telehealth services in drug advertising blitz

FDA takes aim at Hims and other telehealth services in drug advertising blitz

The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy

The Independent UK

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks

Food and Drug Administration Commissioner Martin Makary stated on Friday that Hims Hers Health Inc. (NYSE:HIMS) broke federal law with its Super Bowl commercial promoting weight-loss drugs.

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims Hers Health Inc. (NYSE:HIMS) launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.

Get all your
news in one place.

100's of premium titles.
One news app.

Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire

Wall Street's most crowded shorts are starting to look like powder kegs. Rocket Companies Inc (NYSE:RKT), Oscar Health Inc (NYSE:OSCR), and Hims Hers Health Inc (NYSE:HIMS) are sitting at the top of the market's short-interest leaderboard, each with more than a quarter of their float sold short.

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

What's Going On With Hims & Hers Shares Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy.

Get all your
news in one place.

100's of premium titles.
One news app.

Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4

A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.

CoreWeave, Applied Materials And Hims & Hers Are Among Top 10 Large Cap Losers Last Week (August 11-August 15): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

5 Ways ‘Hims’ Searches Are Shaping Men’s Health Conversations

In recent years, men’s health has shifted from being a quiet, private matter to an open conversation fueled by technology and data. One of the biggest players in that transformation is Hims, the telehealth platform known for discreetly delivering prescription and wellness products straight to consumers. Search data from Hims…

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces

Hims Hers Health Inc. (NYSE:HIMS) stock is trading lower following a media report revealing that the Federal Trade Commission (FTC) has been investigating the company’s business practices for over a year.

Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now

Hims Hers Health Inc. (NYSE:HIMS) has been one of 2025’s hottest telehealth stocks, nearly doubling in value year to date, but a deepening clash with Novo Nordisk A/S (NYSE:NVO) over compounded weight-loss drugs, and shifting FDA rules, has turned momentum into headwinds, sending shares sliding 10% in the past three…

MarketBeat Week in Review – 08/04 - 08/08

Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales

Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to Buy

Hims & Hers falls into a buying opportunity followng the Q2 release and guidance update but investors shouldn't rush to get in, wait for this market to bottom.

1 2 3 4 5

People

178,010 stories

Robert F. Kennedy Jr

Gabriel OsorioMazilli

Jeffrey Neal Johnson

Jordan Chussler

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Federal Reserve

Trump Administration

The Federal Trade Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Affordable Care Act

Places

357,750 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play